Academic Journal
What is the Optimal Time Period for Postponing Nephrectomy in Patients with Renal Cell Carcinoma of Various Stages?
| العنوان: | What is the Optimal Time Period for Postponing Nephrectomy in Patients with Renal Cell Carcinoma of Various Stages? |
|---|---|
| المؤلفون: | GÖKALP, FATİH, Ozkan, Tayyar Alp, Izol, Volkan, Bayazit, Yildirim, SÜER, EVREN, BALTACI, SÜMER, Aslan, Gueven, AKDOĞAN, BÜLENT, Ozen, Haluk, Sozen, Sinan, Tinay, Iker, Celik, Serdar |
| سنة النشر: | 2023 |
| الوصف: | Objective: The coronavirus disease-2019 pandemic has shown us that postponing elective surgeries that include nephrectomy due to renal cell carcinomas (RCC) was undertaken by the physicians to use hospital facilities in a balanced way. However, both urologists and patients were concerned about postponements that may increase the risk of progression. To determine the optimal threshold of postponement time-period for surgery (PTP) and according to the clinical T stages in patients who underwent nephrectomy due to RCC, we used the Urologic Cancer Database-Kidney.Materials and Methods: Patients who underwent detailed clinical T stage analysis with admission and surgery dates were included in the study. PTP was calculated using the dates of definitive preoperative diagnosis and surgery date. Recurrence, overall mortality (OM), recurrence-free survival, and overall survival (OS) were evaluated. The effects of PTP on oncological outcome according to tumor diameter and clinical T stages were also evaluated. We also analyzed the optimal cut-offs of PTP based on clinical T stages.Results: Among 3.258 patients, in the evaluation of 2.946 clinically localized patients, PTP and tumor diameter were found to be important predictors of recurrence (p=0.037 and p<0.001). The optimal PTP of 30 days was found to be an important significant threshold time for the T1 stage and 20 days for T2-4 stage tumors. Patients with longer PTP according to the thresholds shown in this study had higher upstaging for clinical T1a, T2a, and T3 stages; higher recurrence rates for T1b and T2b stages; and higher OM for T2a and T3 tumors. The survival have also shown that more than 20 days of PTP affected OSs for clinical-stage T1 (p=0.019), T2 (p=0.021) and T3 (p=0.007) tumors.Conclusions: All patients with tumors, including clinical T1 tumors, had worsening oncological results as the PTP increased (>20-30 days). |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.4274/uob.galenos.2022.2022.10.2 |
| الاتاحة: | https://doi.org/10.4274/uob.galenos.2022.2022.10.2 https://avesis.hacettepe.edu.tr/publication/details/6ccb8456-f112-4e30-9e80-2e8aa37a7320/oai |
| Rights: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.42508D0E |
| قاعدة البيانات: | BASE |
| DOI: | 10.4274/uob.galenos.2022.2022.10.2 |
|---|